A deal that would enable the Serum Institute of India to develop an AIDS vaccine with Therion Biologics' technology is currently being brokered by the International AIDS Vaccine Initiative (IAVI). IAVI president Seth Berkley hopes that the arrangement will allow research to take place without running into patent battles. The advantages of vaccine development in India include lower expenses, many eager trial participants, and an accommodating government for the growth of the nation's biotech industry. The fact that the patented vaccine-making technology could be usurped by other companies and for other vaccines and that Indian activists' oppose human testing present hurdles for the initiative.